| |
Angeion and Data Innovations
Partner to Create New MedGraphics BreezeConnect™
Interface Provides IMpowered™ Solution for
MedGraphics Cardiorespiratory Diagnostic Customers
SAINT PAUL, Minn. (August 20, 2010) —Angeion Corporation (NASDAQ: ANGN) today announced that it has partnered with Data Innovations to create MedGraphics BreezeConnect, a software interface that provides interfacing options in one comprehensive solution. BreezeConnect is currently available in the United States and is expected to launch internationally in September.
BreezeConnect, part of Angeion’s MedGraphics product line, incorporates Data Innovations’ Instrument Manager™ (IM) to provide connectivity between MedGraphics cardiorespiratory diagnostic systems and a hospital’s electronic medical records. This IMpowered™ solution gives clinicians the ability to improve workflow, reduce department costs, increase productivity and meet “meaningful use” criteria that could qualify their facility for government grant money.
“MedGraphics is expanding its information management product offering both domestically and abroad,” said Rodney A. Young, President and Chief Executive Officer of Angeion. “While we have more than 10 years of interfacing experience, our partnership with Data Innovations gives us a next‐generation global solution for our growing customer base. Our new BreezeConnect adds the functionality of computerized physician order entry that can help our customers reduce errors by minimizing the ambiguity of handwritten orders.”
“Data Innnovations is proud to partner with MedGraphics and we are excited to expand into the cardiorespiratory diagnostics market,” said Lisa Bromley, Worldwide Director of Business Development for Data Innovations. “We look forward to bringing additional value and efficiencies to MedGraphics’ global customer base through the introduction of innovative connectivity and workflow solutions. Additionally, with such a strong emphasis placed on improving patient care through the use of electronic medical records, our companies worked closely together to create a solution to help physicians achieve meaningful use.”
BreezeConnect provides physicians with rapid and complete access to patient diagnostic records via a central shared database. This allows healthcare facilities to enhance the quality of patient care and improve system efficiencies. In addition, BreezeConnect is more user‐friendly, featuring multilingual capabilities, international technical staff and call centers, and a comprehensive support system.
About Angeion Corporation
Founded in 1986, Angeion Corporation acquired Medical Graphics Corporation in December 1999. Medical Graphics develops, manufactures and markets non‐invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics (www.medgraphics.com) and New Leaf (www.newleaffitness.com) brand and trade names. These cardiorespiratory diagnostic systems have a wide range of applications in healthcare as well as health and fitness. The Company’s products are sold internationally through distributors and in the United States through a direct sales force that targets heart and lung specialists located in hospitals, university‐based medical centers, medical clinics and physicians’ offices, pharmaceutical companies, medical device manufacturers, clinical research organizations, health and fitness clubs, personal training studios, and other exercise facilities. For more information about Angeion, visit www.angeion.com.
About Data Innovations
Founded in 1989, Data Innovations (DI) has grown to more than 85 specialists and $21 million in annual sales, becoming the world’s largest clinical and blood laboratory middleware company. With a focus solely on laboratory data management and offices in the United States, Belgium, Brazil, China, France, and the United Kingdom, DI is the only middleware company with a true global scope. Through more than 40 industry business partnerships and working directly with laboratory end users, DI has installed more than 6,500 middleware systems in 65 countries. Instrument Manager (IM) and Laboratory Production Manager (LPM) represent the most complete offerings in the market for pre‐analytical, analytical, and post‐analytical sample processing and non analytical tasks such as equipment maintenance. Almost 1,000 different instruments, automation systems, and information systems are supported. Equally important as DI’s products are its services, which include comprehensive and proactive support, a variety of training options, and on‐site consulting. Labs are continually challenged to decrease turnaround time while handling higher volume and maintaining high data quality despite labor shortages and tightening budgets. DI offerings help the laboratory successfully meet these challenges and supports the company’s vision: To positively impact patient care by applying the discipline of customer intimacy in partnerships that increase efficiencies and improve workflow through delivery of the world’s best total middleware solutions to the clinical laboratory.
The discussion above contains forward-looking statements about Angeion’s future financial results and business prospects that by their nature involve substantial risks and uncertainties. You can identify these statements by the use of words such as “anticipate,” “believe,” “estimate,” “expect,” “project,” “intend,” “plan,” “will,” “target,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Our actual results may differ materially depending on a variety of factors including: (1) national and worldwide economic and capital market conditions; (2) continuing cost-containment efforts in our hospital, clinics, and office market; (3) our ability to successfully operate our business, including our ability to develop, improve, and update our cardiorespiratory diagnostic products and successfully sell these products under the MedGraphics and New Leaf brand names into existing and new markets; (4) our ability to maintain our cost structure at a level that is appropriate to our near to mid-term revenue expectations and that will enable us to increase revenues and profitability as opportunities develop; (5) our ability to achieve constant margins for our products and consistent and predictable operating expenses in light of variable revenues from our clinical research customers; (6) our ability to effectively manufacture and ship products in required quantities to meet customer demands; (7) our ability to expand our international revenue through our distribution partners and our Milan, Italy representative branch office; (8) our ability to successfully defend ourselves from product liability claims related to our cardiorespiratory diagnostic products and claims associated with our prior cardiac stimulation products; (9) our ability to defend our intellectual property; (10) our ability to develop and maintain an effective system of internal controls and procedures and disclosure controls and procedures; and (11) our dependence on third-party vendors. Additional information with respect to the risks and uncertainties faced by the Company may be found in, and the above discussion is qualified in its entirety by, the other risk factors that are described from time to time in the Company’s Securities and Exchange Commission reports, including the Annual Report on Form 10-K for the year ended October 31, 2009.
Contact:
Angeion:
Rodney A. Young, President and Chief Executive Officer, (651) 484-4874
Data Innovations:
www.datainnovations.com
###
|
|
